Market Access US pharma MFN and tariff dynamics: What EU and UK leaders ne... Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.
News Novartis issues a life sciences warning in a 'G-Zero' world Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating."
News EMA and FDA agree 'principles' for AI in drug development The FDA and EMA have come up with guiding principles that they say will underpin future guidance on the use of AI technologies in drug development.
Market Access ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ... At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.
R&D Europe has the tools to fight superbugs. Let’s use them. Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.
Market Access How are the US MFN and German MFG likely to impact pharmaceu... A comparison of the US MFN and German MFG.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.